daratumumab

CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies PURPOSE CD38 is a glycoprotein highly specific to multiple myeloma (MM). Therapeutics using antibodies targeting CD38 have shown promising efficacy. However, the...

I'm starting this thread in a hurry with a rather chaotic and wordy post about this important trial. The team have just sorted themselves out with an English-language donation page that that makes international donations easy, by allowing payment via various means including PayPal and IBAN...

Abstract Daratumumab, an anti-CD38 monoclonal antibody, is an effective therapy for plasma cell myeloma (PCM). However, many initial responders relapse. We compared paired samples from subjects pre-therapy and then acquired resistance to daratumumab. We first used single-cell RNA sequencing and...

Key Points A reduced proportion of CD16+ bone marrow NK cells at diagnosis was associated with decreased daratumumab-mediated NK-cell degranulation. Reduced BM CD16+ NK-cell proportion was associated with reduced likelihood of achieving MRD negativity upon daratumumab-based therapy. Abstract...

https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1607353/abstract Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent need for elucidation of disease mechanisms...

The ME/CFS research team at Haukeland University Hospital in Bergen, Norway (Fluge, Mella, Rekeland, Sørland etc) is recruiting 66 participants for a new placebo-controlled trial on Daratumumab as a potential treatment for ME/CFS. The duration for participants is 72 weeks. The participants will...

What is this study about? This clinical trial is focused on studying the effects of a medication called daratumumab on patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). ME/CFS is a condition characterized by extreme fatigue that doesn’t improve with rest and can worsen...

Posted under Germany, but giving it its own thread https://events.mecfs-research.org/en/events/conference_2025 Agenda https://events.mecfs-research.org/en/events/conference_2025/agenda Features everybody’s favorite serious hard-core ME/CFS researcher David P*trino. 12.05.2025 - Monday...

Commercialisation of HLX15 (daratumumab) https://www.businesswire.com/news/home/20250206161649/en/Dr.-Reddy’s-enters-into-collaboration-with-Henlius-for-commercialization-of-HLX15-daratumumab-a-biosimilar-candidate-to-Darzalex®-Darzalex-Faspro®-in-the-U.S.-and-Europe

Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy Anne Louise Oaklander, Julia Allen, Nadja Dietliker, Einar P. Wilder-Smith OBJECTIVES To expand understanding of the pathogenesis, presentations, and treatment of initially idiopathic small fiber polyneuropathy (SFN). METHODS...

https://rmdopen.bmj.com/content/9/3/e003464 Here, we report the first two cases of patients with severe complications of SjD, refractory to RTX and successfully treated with daratumumab.

With EMEC we are trying to set up a meeting with representatives of The European Federation of Pharmaceutical Industries and Associations (EFPIA). We are compiling a list of drugs that seem most promising for the treatment of ME/CFS and the pharmaceutical companies that make them. An example...

Fluge et al are recruiting six moderate to severe ME patients for a pilot trial on Daratumumab. Participants need to be able to travel to Haukeland University Hospital in Bergen and been diagnosed according to the Canadian criteria from 2003. They need to be between 18 and 65 years old and...

Summary Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but they are...